Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

151 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-05-14

Study Completion Date

2025-10-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase I trial studies the side effects and best dose of vandetanib and everolimus when given together in treating patients with cancer that has spread to other places in the body. Vandetanib and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Erlotinib in Combination With Bortezomib

NCT00895687

Advanced Cancer

COMPLETED PHASE1

Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

NCT00574366

Breast Cancer

COMPLETED PHASE1

Erlotinib in Combination With Pralatrexate in Advanced Malignancies

NCT01532011

Advanced Cancers Solid Tumors

COMPLETED PHASE1

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor

NCT00412061

Carcinoid Tumor Malignant Carcinoid Syndrome

COMPLETED PHASE3

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

NCT01797523

Endometrial Cancer

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) or highest dose level, and the dose-limiting toxicity (DLT) of vandetanib (a multi-kinase inhibitor of epidermal growth factor receptor \[EGFR\], vascular endothelial growth factor receptor \[VEGFR\] and ret proto-oncogene \[RET\] inhibitor) when used in combination with everolimus (a mammalian target of rapamycin \[mTOR\] inhibitor) in advanced cancer.

II. Preliminary descriptive assessment of the anti-tumor efficacy of the combination.

III. Preliminary optional assessment of the pharmacokinetic, pharmacodynamic markers of target inhibition and correlates of response.

OUTLINE: This is a dose-escalation study.

Patients receive vandetanib orally (PO) once daily (QD) and everolimus PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment patients are followed up between 14-28 days at the discretion of the treating physician.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Malignant Neoplasm Metastatic Malignant Neoplasm Recurrent Malignant Neoplasm Refractory Malignant Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment (vandetanib, everolimus)

Patients receive vandetanib PO QD and everolimus PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Group Type EXPERIMENTAL

Everolimus

Intervention Type DRUG

Given PO

Laboratory Biomarker Analysis

Intervention Type OTHER

Optional correlative studies

Pharmacological Study

Intervention Type OTHER

Optional correlative studies

Vandetanib

Intervention Type DRUG

Given PO

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Everolimus

Given PO

Intervention Type DRUG

Laboratory Biomarker Analysis

Optional correlative studies

Intervention Type OTHER

Pharmacological Study

Optional correlative studies

Intervention Type OTHER

Vandetanib

Given PO

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

42-O-(2-Hydroxy)ethyl Rapamycin Afinitor Certican RAD 001 RAD001 Votubia Zortress AZD6474 Caprelsa Zactima ZD-6474 ZD6474

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with advanced or metastatic cancer that is refractory to standard therapy, relapsed after standard therapy, or who have no standard therapy available that improves survival by at least three months.
* Patients must be at least 3 weeks beyond their previous cytotoxic chemotherapy.
* Patient must be at least 5 half-lives or 3 weeks, whichever is shorter, from their previous targeted or biologic therapy; In addition, patients must be at least 3 weeks beyond the last session of radiation therapy. Local palliative radiation therapy that is not delivered to all target lesions is allowed immediately before or during treatment.
* ECOG performance status should be less or equal to 3
* Patients must have organ and marrow function defined as: Absolute neutrophil count more or equal to 750/mL; platelets more or equal to 50,000/mL; creatinine less or equal to 3x ULN; total bilirubin less than or equal to 3.0.
* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence).

Exclusion Criteria

* Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, uncontrolled asthma, need for hemodialysis, need for ventilatory support.
* Pregnant or lactating women.
* History of hypersensitivity to vandetanib, lactose, murine products, or any component of the formulation.
* History of hypersensitivity to sirolimus, temsirolimus, everolimus.
* History of hypersensitivity to any component of the formulation.
* Patients unwilling or unable to sign informed consent document.
* Presence of cardiac disease that, in the opinion of the Investigator, increases the risk of ventricular arrhythmia.
* History (within the last 3 months) or presence of stroke/cerebrovascular accident.
* Congenital long QT syndrome.
* QTcF interval greater than 500 ms that is not correctable to less than 500ms such as with cessation of a causative medication, etc.
* History of myocardial infarction within 6 months with a residual arrhythmia that in the opinion of the Investigator, increases the risk of ventricular arrhythmia.
* Presence of a symptomatic bradyarrhthmia or uncompensated heart failure.

Eligible Sex

ALL

Accepts Healthy Volunteers

No